Lantheus Holdings, Inc. with ticker code (LNTH) now have 10 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $128.00 and $96.00 with the average share target price sitting at $104.40. (at the time of writing). Given that the stocks previous close was at $81.13 and the analysts are correct then we can expect a percentage increase in value of 28.7%. The 50 day MA is $74.45 and the 200 day moving average is $66.17. The market capitalization for the company is 5.65B. The current share price for the company is: $81.48 USD
The potential market cap would be $7,267,453,361 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 12.42, revenue per share of $19.93 and a 19.01% return on assets.
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company’s license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
